40mg

DRUG2 trials

Sponsors

The First Hospital of Jilin University, Crinetics Pharmaceuticals Inc.

Conditions

Ankylosing Spondylitis• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Phase 1

A single-center, randomized, double-blind, placebo-controlled multiple-ascending dose study of QX002N injection

Active, not recruitingChiCTR2000034090

The First Hospital of Jilin UniversityAnkylosing Spondylitis

Start: 2020-08-01Updated: 2020-06-29

Phase 2

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

Not yet recruitingCTIS2025-522648-42-01

Crinetics Pharmaceuticals Inc.• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Target: 25Updated: 2026-09-29